Company Overview

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines that modulate the effects of cortisol. The company operates primarily within the biotechnology and pharmaceutical industries, with a specialization in endocrine and metabolic disorders. Its business model centers on developing proprietary cortisol modulators to address diseases driven or exacerbated by excess cortisol activity.

The company’s primary revenue driver is Korlym, an oral glucocorticoid receptor antagonist approved for the treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with type 2 diabetes mellitus or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery. Corcept has positioned itself uniquely by focusing exclusively on cortisol modulation, an area with limited direct competition. Founded in 1998, the company evolved from a research-focused enterprise into a commercial-stage pharmaceutical company following the U.S. approval of Korlym in 2012.

Business Operations

Corcept generates substantially all of its revenue from the sale of Korlym in the United States, where it maintains a dedicated commercial organization targeting endocrinologists and specialized healthcare providers treating Cushing’s syndrome. The company’s operations also include an extensive research and development program focused on selective cortisol modulators intended to improve efficacy and safety compared to first-generation compounds.

The company controls a proprietary drug discovery and development platform focused on glucocorticoid receptor antagonism. Its clinical-stage pipeline includes investigational compounds such as relacorilant and dazucorilant, which are being evaluated for indications including Cushing’s syndrome, cancer, and neuropsychiatric disorders. Based on publicly available SEC filings, Corcept conducts its operations primarily through the parent company and does not report material operating subsidiaries or joint ventures; data on minor or non-operating entities is inconclusive based on available public sources.

Strategic Position & Investments

Corcept’s strategic direction emphasizes expanding its cortisol modulation platform beyond Cushing’s syndrome into oncology and neurological diseases where cortisol signaling is believed to play a role in disease progression or treatment resistance. Growth initiatives are primarily internally driven through clinical development rather than through large-scale acquisitions.

The company has made sustained investments in late-stage clinical trials, particularly for relacorilant, including studies in hypercortisolism and solid tumors. Corcept has not reported any transformative acquisitions or a diversified investment portfolio, instead favoring organic growth and intellectual property development. Its strategy reflects a long-term focus on creating a franchise of cortisol-modulating therapies across multiple disease categories.

Geographic Footprint

Corcept is headquartered in Redwood City, California, and its commercial operations are concentrated in North America, specifically the United States. All approved product sales are currently U.S.-based, and the company does not report meaningful international commercial revenue.

Research and development activities are also primarily U.S.-based, though the company conducts certain clinical trials that may include investigational sites outside the United States. Despite limited direct international operations, Corcept’s clinical programs and intellectual property strategy provide a foundation for potential future expansion into Europe and other global markets, subject to regulatory approvals.

Leadership & Governance

Corcept was founded by Joseph K. Belanoff, who continues to play a central role in shaping the company’s scientific and strategic direction. The leadership team emphasizes a research-driven culture with a long-term focus on mechanistic understanding of disease and disciplined clinical development.

Key executives include:

• Joseph K. Belanoff – Chief Executive Officer
• Christopher K. Taylor – Chief Financial Officer
• William Guyer – Chief Development Officer
• Patrick R. Hsu – Chief Operating Officer

The company is governed by a board of directors with experience in biotechnology, medicine, and finance, and management has consistently articulated a strategy centered on scientific rigor, focused indications, and maintaining full commercial control over its core products.